145 related articles for article (PubMed ID: 10588977)
1. The role of international environmental agreements in metered-dose inhaler technology changes.
Forte R; Dibble C
J Allergy Clin Immunol; 1999 Dec; 104(6):S217-20. PubMed ID: 10588977
[TBL] [Abstract][Full Text] [Related]
2. Advances in metered dose inhaler technology with the development of a chlorofluorocarbon-free drug delivery system.
Ross DL; Gabrio BJ
J Aerosol Med; 1999; 12(3):151-60. PubMed ID: 10623331
[TBL] [Abstract][Full Text] [Related]
3. The ozone layer and metered dose inhalers.
Boulet LP
Can Respir J; 1998; 5(3):176-9. PubMed ID: 9707462
[TBL] [Abstract][Full Text] [Related]
4. Transition to CFC-free metered dose inhalers--into the new millennium.
McDonald KJ; Martin GP
Int J Pharm; 2000 May; 201(1):89-107. PubMed ID: 10867268
[TBL] [Abstract][Full Text] [Related]
5. Moisture transport into chlorofluorocarbon-free metered dose inhalers.
Williams G
J Allergy Clin Immunol; 1999 Dec; 104(6):S227-9. PubMed ID: 10588979
[TBL] [Abstract][Full Text] [Related]
6. Economics of "essential use exemptions" for metered-dose inhalers under the Montreal Protocol.
DeCanio SJ; Norman CS
J Environ Manage; 2007 Oct; 85(1):1-8. PubMed ID: 16982135
[TBL] [Abstract][Full Text] [Related]
7. New delivery systems and propellants.
Dolovich M
Can Respir J; 1999; 6(3):290-5. PubMed ID: 10393290
[TBL] [Abstract][Full Text] [Related]
8. Switching to CFC-free beclometasone for asthma.
Drug Ther Bull; 2008 Jun; 46(6):46-8. PubMed ID: 18525059
[TBL] [Abstract][Full Text] [Related]
9. The president speaks: prevention is best: lessons from protecting the ozone layer.
Woodcock A
Thorax; 2012 Dec; 67(12):1028-31. PubMed ID: 23019254
[TBL] [Abstract][Full Text] [Related]
10. Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol.
Bronsky E; Ekholm BP; Klinger NM; Colice GL
J Asthma; 1999; 36(1):107-14. PubMed ID: 10077140
[TBL] [Abstract][Full Text] [Related]
11. The Montreal Protocol and essential use exemptions.
D'Souza S
J Aerosol Med; 1995; 8 Suppl 1():S13-7. PubMed ID: 10150490
[TBL] [Abstract][Full Text] [Related]
12. The CFC to HFA transition and its impact on pulmonary drug development.
Leach CL
Respir Care; 2005 Sep; 50(9):1201-8. PubMed ID: 16122403
[TBL] [Abstract][Full Text] [Related]
13. The change to non-CFC metered dose inhalers.
Rubinfeld A
Aust Fam Physician; 1997 Dec; 26(12):1412-4. PubMed ID: 9470296
[TBL] [Abstract][Full Text] [Related]
14. Loss of bronchodilator medication in priming a conventional metered dose inhaler: a cost of treating asthma.
Ross RN
Med Interface; 1997 Apr; 10(4):141-6. PubMed ID: 10166801
[TBL] [Abstract][Full Text] [Related]
15. Sustainability in Inhaled Drug Delivery.
Wilkinson AJK; Anderson G
Pharmaceut Med; 2020 Jun; 34(3):191-199. PubMed ID: 32500439
[TBL] [Abstract][Full Text] [Related]
16. Use of hydrofluoroalkane propellant delivery system for inhaled albuterol in patients receiving asthma medications.
Boccuzzi SJ; Wogen J; Roehm JB
Clin Ther; 2000 Feb; 22(2):237-47. PubMed ID: 10743983
[TBL] [Abstract][Full Text] [Related]
17. Chlorofluorocarbon to hydrofluoroalkane formulations: an industry perspective.
Atkins P
J Allergy Clin Immunol; 1999 Dec; 104(6):S268-70. PubMed ID: 10588988
[TBL] [Abstract][Full Text] [Related]
18. Review of therapeutically equivalent alternatives to short acting beta(2) adrenoceptor agonists delivered via chlorofluorocarbon-containing inhalers.
Hughes DA; Woodcock A; Walley T
Thorax; 1999 Dec; 54(12):1087-92. PubMed ID: 10567628
[TBL] [Abstract][Full Text] [Related]
19. Carbon footprint impact of the choice of inhalers for asthma and COPD.
Janson C; Henderson R; Löfdahl M; Hedberg M; Sharma R; Wilkinson AJK
Thorax; 2020 Jan; 75(1):82-84. PubMed ID: 31699805
[TBL] [Abstract][Full Text] [Related]
20. A United States regulator's perspective on the ongoing chlorofluorocarbon transition.
Meyer RJ
J Allergy Clin Immunol; 1999 Dec; 104(6):S236-8. PubMed ID: 10588981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
